CDK2 and ovarian carcinoma: The levels of p-RB, cyclin D1, cyclin E, CDK2, CDK4, or CDK6 by RPS6-KD were reduced in NSCLC cells [38], ovarian cancer cells [40], and drug-resistant melanoma cells [39].